1 |
Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000;58:1841-1850.
DOI
ScienceOn
|
2 |
Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 2001;60:587-596.
DOI
ScienceOn
|
3 |
Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-l mutant. PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol. 2008;19:329-338.
DOI
ScienceOn
|
4 |
Gonzalez J, Klein J, Chauhan SD, Neau E, Calise D, Nevoit C, Chaaya R, Miravete M, Delage C, Bascands JL, Schanstra JP, Buffin-Meyer B. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis. Exp Biol Med (Maywood). 2009;234:1511-1518.
DOI
ScienceOn
|
5 |
de Martimprey H, Vauthier C, Malvy C, Couvreur P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA Eur J Pharm Biopharm. 2009;71:490-504.
DOI
ScienceOn
|
6 |
Fisher EJ, McLennan SV, Yue DK, Turtle JR. High glucose reduces generation of plasmin activity by mesangial cells. Microvasc Res. 1997;53:173-178.
DOI
ScienceOn
|
7 |
Cho HK, Yang EK, Han HS, Lee WJ, Phillips ML. Effect of brain angiotensin II receptor antagonists and antisense oligonucleotide on drinking and renal renin in rats. Korean J Physiol Pharmacol. 2000;4:137-142.
|
8 |
Oh JH, Ha H, Yu MR, Lee HB. Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int. 1998;54:1872-1878.
DOI
ScienceOn
|
9 |
Jiang Z, Seo JY, Ha H, Lee EA, Kim YS, Han DC, Uh ST, Park CS, Lee HB. Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun. 2003;309:961-966.
DOI
ScienceOn
|
10 |
Kanalas JJ, Hopfer U. Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol. 1997;8:184-192.
|
11 |
Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem. 1994;269:14149-14152.
|
12 |
Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005;67:1297-1307.
DOI
ScienceOn
|
13 |
Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol. 2009;5:203-211.
DOI
ScienceOn
|
14 |
Lee EA, Seo .JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up.regulation in mesangial cells and in diabetic kidney. Kidney Int. 2005;67:1762-1771.
DOI
ScienceOn
|
15 |
Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol. 2003;14:1487-1495.
DOI
ScienceOn
|
16 |
Collins SJ, Alexander SL, Lopez-Guisa JM, Cai X, Maruvada R, Chua SC, Zhang G, Okamura DM, Matsuo S, Eddy AA. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephrol. Exp Nephrol. 2006;104:e23-e34.
DOI
ScienceOn
|
17 |
Seo JY, Park J, Yu MR. Kim YS, Ha H, Lee HB. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta 1 during renal fibrosis in diabetes. Am J Nephrol. 2009;30:481-490.
DOI
ScienceOn
|
18 |
Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest. 2003;112:379-388.
DOI
ScienceOn
|
19 |
Huang Y, Border WA, Lawrenre DA, Noble NA. Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1(PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol. 2009;297:F1045-F1054.
DOI
ScienceOn
|
20 |
Neckers L, Whitesell L. Antisense technology: biological utility and practical considerations. Am J Physiol. 1993;265:L1-L12.
DOI
|
21 |
Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989;38:1077-1081.
DOI
ScienceOn
|
22 |
Schnaper HW. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol. 1995;9:104-111.
|
23 |
Wong AP, Cortez SL, Bariros WH. Role of plasmin and gelatinase in extracellular matrix degradation by cultured rat mesangial cells. Am J Physiol. 1992;263:F1112-F1118.
|
24 |
Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol. 1999;10:790-795.
|
25 |
Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol. 2002;192:160-170.
DOI
ScienceOn
|
26 |
Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067-1072.
DOI
|
27 |
Ingelfinger JR. Forestalling fibrosis. N Engl J Med. 2003;349:2265-2266.
DOI
ScienceOn
|
28 |
Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol. 2006;17:2999-3012.
DOI
ScienceOn
|